MAY 04, 2016
In this interview from ARVO 2016, Dr. Daniel Martin discusses a long-term analysis from the Comparison of AMD Treatments Trials (CATT), which shows mean visual acuity was 3 letters worse at 5 years compared with baseline and 11 letters worse than at 2 years. Additionally, this decrease in vision was accompanied by expansion of the size of the total neovascular complex and increased rates of geographic atrophy. Still, he emphasizes that half of the patients had VA of 20/40 or better, which highlights the tremendous advances over the past 15 years in preserving vision for a large proportion of patients. Read the full text of the study here.